Aiforia vs Primaa (2026)
Both are CE marked algorithm vendors with no FDA clearance and an A on AI centrality, but they diverge on maturity and specialty. If you want broad, already adopted multi tumor coverage with published deployment, start with Aiforia. If you need dermatopathology specifically, where almost nothing else exists, or you want algorithms that run across four host platforms with minimal lock in, start with Primaa, accepting thinner published evidence. Aiforia spans five tumor types plus lymph node with named clinical deployments and a model building engine. Primaa is narrower, covering breast and skin, but its Cleo Skin is described as the first CE-IVDR tool in dermatopathology, and its algorithms run inside four separately available platforms, which lowers the risk of being locked to one workspace.
- Breadth and adoption: CE-IVD suites across five tumor types plus lymph node, with named clinical deployments at AP-HP, Nantes, Institut Curie, and a Lombardy regional selection, a deeper adoption record than Primaa, whose validation studies were still pending at review.
- A model building engine via Aiforia Create.
- Vendor stability visibility from its Helsinki listing.
- Dermatopathology coverage almost nothing else here offers: Cleo Skin is described as the first CE-IVDR tool in that specialty, a genuinely underserved area rather than the crowded breast application.
- The clearest multi platform integration of any algorithm only vendor in the index: Cleo runs inside AISight, Proscia, PathPresenter, and Gestalt, three of them separately indexed, which lowers platform lock in.
- An assistive posture measured as such: its dermatopathology validation was designed to compare pathologist performance with and without the AI, treating the human and machine pairing as the unit of evaluation.
This comparison is published by AI Health Index, an independent research platform that compares healthcare AI vendors objectively. Aiforia and Primaa are each graded against the same capability taxonomy, from each vendor's own public materials and the regulatory record, under the AI Health Index verification standard. No vendor pays for placement, and no vendor has reviewed this page. How this evidence is graded
Plain facts
| Fact | Aiforia | Primaa |
|---|---|---|
| Primary category | Digital Pathology AI | Digital Pathology AI |
| Founded | 2013 | 2018 |
| Headquarters | Helsinki, Finland | Paris, France |
| Website | aiforia.com | primaalab.com |
Side by Side
Each record in one paragraph
Written to be quoted whole. Each paragraph states what the AI Health Index verified about the vendor, with the caveats attached. Generated from this pair’s live capability grades, so it moves when a grade moves.
The AI Health Index awards Aiforia its top capability grade on AI Centrality and Security Certifications and Trust Center. Set against Primaa, Aiforia grades higher on several axes, including Model and Technology Transparency, HIPAA and BAA Posture and Security Certifications and Trust Center. Grades reflect evidence the AI Health Index could verify at the last review, so a low grade records disclosure the vendor has not published rather than a capability it has been shown to lack.
Source: AI Health Index, July 2026
The AI Health Index awards Primaa its top capability grade on AI Centrality and EHR and Interoperability Depth. Set against Aiforia, Primaa grades higher on several axes, including Model Supply Chain Disclosure, AI Safety and PHI Stewardship and EHR and Interoperability Depth. Its thinnest published disclosure sits on AI Liability and Recourse. Grades reflect evidence the AI Health Index could verify at the last review, so a low grade records disclosure the vendor has not published rather than a capability it has been shown to lack.
Source: AI Health Index, July 2026
Questions buyers ask
Should we choose Aiforia or Primaa?
On the axes where the AI Health Index separates them, Aiforia grades higher on several axes, including Model and Technology Transparency, HIPAA and BAA Posture and Security Certifications and Trust Center, and Primaa grades higher on several axes, including Model Supply Chain Disclosure, AI Safety and PHI Stewardship and EHR and Interoperability Depth. Neither leads on the greater share of scored axes, so the decision turns on which constraint is binding rather than on an overall winner.
Where do Aiforia and Primaa differ most?
The widest separation the AI Health Index records between Aiforia and Primaa is on Security Certifications and Trust Center, where Aiforia grades A and Primaa grades C. That axis sits in the Regulatory and Compliance group, so it should carry the most weight for a buyer whose binding constraint is where regulatory exposure sits and who carries it.
Where do Aiforia and Primaa grade the same?
The AI Health Index grades Aiforia and Primaa the same on several axes, including AI Centrality, Autonomy and Oversight Model and Clinical and Operational Evidence. Neither holds an advantage the index can evidence on those axes, so they should not carry weight in a selection between these two.
What have Aiforia and Primaa not disclosed?
At the last review, at least one of Aiforia and Primaa published thin or absent detail on AI Liability and Recourse. The AI Health Index treats an absent disclosure as a gap in the public record rather than a failure of the product, so these are the axes to get in writing during diligence instead of inferring from the grade.
Related comparisons
Other published head to head assessments involving these vendors or their closest peers. The full set for this category is on the Digital Pathology AI page.
Both are CE-IVD only with no FDA clearance, and neither publishes pricing, a security attestation, or subgroup performance. Primaa is the thinner evidenced of the two: its Cleo Breast and Cleo Skin validation studies were still underway and unpublished at review, so its clinical evidence and model transparency grade below Aiforia's.
The dermatopathology gap matters because skin AI carries a well documented performance concern across skin tones, and Primaa has published no subgroup analysis against it. One scope caveat: Cleo Skin's regulatory status varies by route, listed as CE-IVDR in some contexts and research use only in the AISight integration, so a buyer must confirm which applies to their market. Aiforia's efficiency figures are vendor quoted and not independently verified, and its integration is asserted through partnerships rather than enumerated.